Yes, even frail HFpEF patients see significant benefits when treated with semaglutide. Researchers believe these new data may help ease the minds of cardiologists everywhere.

Martha Gulati, MD, co-chair on a new joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology, discusses the dire need she sees to boost prevention efforts for heart failure.

The newly approved drug-device combination helps patients manage their own treatment from the comfort of home. 

The flexible device is attached to the inner wall of the left ventricle during a minimally invasive procedure. It was designed to reduce the size of the left ventricle over time.

The document provides an in-depth look at the close relationship between inflammation and cardiovascular disease. "The time for taking action has now arrived," the authors wrote. 

A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time.

Three leading medical societies collaborated on the new document, providing detailed recommendations that cover a wide variety of technologies and clinical scenarios.